Preimplantation Genetic Diagnosis Market is Segmented By Product Type (Reagents & Consumables, Instruments, Software & Services), By Technology (Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Comparative Genomic Hybridization (CGH), Other), By Application(Aneuploidy, Structural Chromosomal Abnormalities, Single Gene Disorders, X-linked Disorders, Gender Identification, Other) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.
The Preimplantation Genetic Diagnosis Market size is estimated to reach at a high CAGR during the forecast period 2022-2029
Preimplantation genetic testing is a technique used before pregnancy to detect genetic defects in embryos created through in vitro fertilization (IVF).
Preimplantation Genetic Diagnosis Market Scope:
|
Metrics |
Details |
|
Market CAGR |
High |
|
Segments Covered |
By Product Type, By Technology, By Application, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
Market Dynamics
Many factors are influencing the market growth of the preimplantation genetic diagnosis market. For instance, the advancement in diagnostic procedures in gene testing is expected to drive the market.
The advancement in the diagnostic procedures in gene testing is expected to drive the market in the forecast period
Many recent research developments in genomics have included the ongoing transition from traditional ‘monogenic genetics to comprehensive testing of the human genome by integrating massively parallel sequencing approaches and advanced bioinformatics. Currently, it is possible to elucidate the entire human genome's single nucleotide variation (SNV), copy number variation (CNV), and structural variation (SV), i.e., beyond the original medical indication for which a patient (along with their family) were referred for genetic testing. These technological advances can be seen in expanded carrier screening (ECS), the elimination of gamete donor anonymity, preimplantation genetic testing (PGT), and non-invasive prenatal testing (NIPT), as well as an understanding of the underlying causes of male and female infertility.
PGD/PGS (Preimplantation Genetic Diagnosis and preimplantation Genetic Screening) has become more common in IVF clinics over the years, assisting thousands of patients in having healthy babies. With the rapid advancement of biotechnologies, new methods have been developed to reduce the negative impact on embryo development while increasing the accuracy and efficiency of PGD/PGS. Meanwhile, several new non-invasive sampling methods, such as time-lapse imaging technology, BF sampling, and cell-free nucleic acid collection, have been introduced into the field.
Limitations associated with the genetic diagnosis is expected to hamper the market
Preimplantation genetic testing cannot detect all genetic abnormalities in a fetus. For example, it cannot detect all microdeletions or microduplications, nor can it detect de novo pathogenic variants. Patients and health care providers should be aware that a negative preimplantation genetic test result does not guarantee the birth of a child free of genetic abnormalities. Counselling about prenatal genetic screening or testing should be a collaborative process centred on the patient's risk, reproductive goals, and preferences.
Preimplantation genetic testing has many limitations, including difficulties in detecting microdeletions and microduplications, de novo variants, and imprinting disorders. The detection of mosaicism during preimplantation genetic testing-aneuploidy-has emerged as a new problem. Mosaicism is defined as the presence of two or more cell populations with different chromosomal complements in the same embryo.
COVID-19 Impact Analysis
The global preimplantation genetic diagnosis market was moderately affected. It is not clear whether the COVID-19 pandemic influenced pregnant women's decision to use prenatal genetic tests. The virus elicited a rapid and massive response across healthcare systems, with telehealth implementation serving as a key component of these changes to reduce the risk of viral exposure among patients, healthcare providers, and communities, given the potential effects of COVID-19 on maternal and neonatal outcomes, as well as the importance of prenatal genetic testing for the delivery of high-quality prenatal care. Most of the diagnosis and testing procedures were postponed or delayed. At the same time, most people were scared that they would get infected. Hence, the market was affected by the impact of COVID-19 partially.
Segment Analysis
Aneuploidy test type is projected to dominate the market in the forecast period
Aneuploidy is a genetic disorder that occurs due to an abnormal number of chromosomes, such as a human cell with 45 or 47 chromosomes instead of the usual 46. The increasing incidence of aneuploidy and its diagnosis is expected to drive the preimplantation genetic diagnosis market. For instance, the most common aneuploidies in humans are trisomies, accounting for about 0.3 per cent of live births. Trisomies are distinguished by an additional chromosome, bringing the total number of chromosomes to 47. Trisomies, with a few exceptions, do not appear to be compatible with life. Trisomies account for approximately 35% of spontaneous abortions.
Preimplantation genetic testing-aneuploidy has been proposed as a method to detect whole chromosome aneuploidy before the transfer, potentially increasing live birth rates and decreasing early pregnancy failure rates. The original technique, which used fluorescence in situ hybridization, was limited to a few chromosomes. Preimplantation genetic testing-aneuploidy has now been expanded to include evaluation of all chromosomes using techniques such as array comparative genomic hybridization and next-generation sequencing.PGT-A is primarily used to screen embryos for whole-chromosome abnormalities. Before its use, the selection of embryos for transfer was primarily based on morphologic criteria, but many women did not achieve pregnancy despite the transfer of morphologically optimal embryos.
Global Preimplantation Genetic Diagnosis Market-Geographical Analysis
The global preimplantation genetic diagnosis market is expected to grow in the North America region in the forecast period
The presence of better healthcare facilities in this region is expected to boost the market in the forecast period. Pre-implantation genetic diagnosis (PGD) is offered by more than 75% of fertility clinics in the United States, and PGD is used in 4–6% of IVF procedures each year. While PGS can screen for aneuploidy in IVF patients, PGD is also commonly used to screen for specific genetic disorders.
In 2018, 306,197 ART cycles were performed in the United States. Because of ART, approximately 73,831 live births occurred that year. In the United States, IVF has resulted in over one million babies. Thirty-three per cent of IVF mothers become pregnant during their first cycle. The rise in IVF procedures is expected to increase the market growth of the preimplantation genetic diagnosis market.
Competitive Landscape
The global preimplantation genetic diagnosis market is moderately competitive with the company's investments, mergers and launches. Some of the major key players in the market are Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Perkinelmer, Inc., Coopersurgical, Inc. (A Subsidiary of the Cooper Companies, Inc.), Abbott Laboratories, Natera, Inc., Takara Bio Usa Holdings, Inc., Yikon Genomics, Invicta Genetics
Agilent Technologies, Inc.
Overview: Agilent Technologies, Inc. is an American analytical instrument development and manufacturing company that serves markets worldwide with its products and services. The company's global headquarters are in Santa Clara, California. The company was founded as a spin-off by Hewlett-Packard in 1999.
Product Portfolio: The company’s Agilent OnePGT contains reagents for genome-wide amplification, library preparation, and software and cloud services.
Key Development: On October 30, 2018, Agilent Technologies Inc. launched Agilent OnePGT, a genome-wide next-generation sequencing (NGS) solution for preimplantation genetic testing (PGT).
